Transcript How FDG
Radiopharmaceutical Production FDG Synthesizer Operation STOP Operation of synthesizers All the commercial syntheizers are based on the Hamacher synthesis [1]. Some use base hydrolysis while others use acid hydrolysis. Each has some advantages and disadvantages. The final sterilization may be done either with a 0.22 micron membrane filter or by steam autoclaving. Content 1. 2. 3. Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand 4. Labeling of glucose with F-18 5. Removal of protecting groups 6. Purification of final product 7. Sterilization 8. QC sample removal 9. Dispensing 10. QC Control During Synthesis 1. HAMACHER, K., COENEN, H.H., STOCKLIN, G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27(2):235-8. STOP SYNTHESIS OF [18F]FDG PRODUCT Preparation 18F- FDG “NAKED” FLUORIDE Cleaning O O H O H Synthesis Module 18F PRECURSOR Nucleophilic substitution O H Deprotection INTERMEDIATE STOP 18F O H [18F]FDG Radiopharmaceutical Production Overall FDG Synthesis Scheme Starting with the MannoseTriflate FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP The protecting groups keep the fluoride from reacting at positions other than the 2 position on the ring Both FDG and glucose are formed in the synthesis See the following slides for some key features of the synthesis. Key Features of the Synthesis Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • • Why the precursor molecule needs acetyl protection? This is to make substitution reaction possible. Fluoride anion tends to form very strong hydrogen bonds with any type of polar groups such as hydroxyl groups present in sugars. This strong hydrogen bond formation prevents the fluoride from reacting in the desired nucleophilic substitution. Therefore, all hydroxyl groups of precursor are protected by acetyl ester protection. Key Features of the Synthesis Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • • Why Kryptofix 2.2.2 is used? Kryptofix 2.2.2 (4,7,13,16,21,24-hexaoxa-1,10diazabicyclo[8,8,8]hexacosane) is a phase transfer catalyst. On one hand, it helps to solubilize the [18F]fluoride anion in an anhydrous reaction solvent (acetonitrile). On the other hand, it helps to separate the strong ion pair formed between [18F]fluoride and potassium by ‘caging’ the potassium cation. This helps to make fluoride free from interaction with potassium and make it more available for nucleophilic displacement reaction. Key Features of the Synthesis Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • • What is TBA? TBA stands for tetrabutylammonium carbonate, which is an alternative phase transfer catalyst, and may be used instead of Kryptofix 2.2.2.. Some synthesizers could use either TBA or Kryptofix. When TBA is used in a synthesis, a suitable quality control procedure for estimation of TBA present in the FDG product is needed instead of Kryptofix 2.2.2. A minor disadvantage of TBA use is that it needs to be converted from commercially available hydroxide into carbonate form. In this book we make assumption that Kryptofix is used as the phase transfer catalyst. Key Features of the Synthesis Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • • How is D-glucose (DG) (4) formed in the reaction? D-glucose is always formed as a by-product of FDG synthesis from the unreacted precursor (1) by hydrolysis of tetraacetylmannose triflate into D-glucose. D-Glucose is mentioned in International Pharmacopoeia as a principal peak in the quality control test for chemical purity. There are no limits for its presence in the final formulation, because it is a natural compound present in human blood in large concentrations. Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Extraction of F-18 from target water • After irradiation of enriched water, the mixture 18F-/18O[H2O] is transferred from the target onto a pre-conditioned anion exchange separation cartridge such as QMA (quaternary ammonium anion exchange) SepPakTM column. The 18F- ions are retained on the cartridge while unused [18O]H2O and the cationic and other impurities from the target are removed and collected in a waste vial. The trapped 18F- is subsequently eluted from the cartridge with a solution containing K2CO3 and the phase transfer catalyst (Kryptofix 2.2.2), in acetonitrile and pharmaceutical grade water. 18F-KF/Krytofix complex eluted is collected in the reaction vial. Quantities of K2CO3 and Kryptofix 2.2.2 vary depending upon the synthesis module. Radiopharmaceutical Production Drying of Fluoride with TBA or Cryptand • Effective dryness of fluoride (virtual freedom from water) is a critical factor for the nucleophilic reaction to occur efficiently and with eventual high yield of FDG. The required dryness is achieved through repeated azeotropic evaporation (typically 3 times) with anhydrous acetonitrile at ~85C under inert gas or vacuum. It is essential that during each solvent removal step, the mixture to taken to complete dryness, and also that the vessel temperature does not exceed 100ºC in order to prevent decomposition of Kryptofix 2.2.2. • Nucleophilic displacement reactions with fluoride are known to be quite difficult and unpredictable because of the fluoride ion being a weak nucleophile in an aqueous media, leading to very poor yields. In a polar aprotic media such as acetonitrile, fluoride undergoes nucleophilic reactions rather quickly. However, for fluoride to become an effective nucleophile, it must be available as reactive fluoride. The 18F-/K2CO3/Kryptofix 2.2.2 complex is effectively an organic cation/inorganic anion salt soluble in acetonitrile making the [18F]fluoride available in a highly reactive form. FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Labeling of glucose with F-18 Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • In the synthesis of 18F-FDG based upon the method of Hamacher et. al. [1], the 1,3,4,6-tetraO-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose (mannose triflate) precursor reacts with [18F]Fluoride through nucleophilic displacement. Although various precursor substrates have been described in the literature, the use of triflate as the leaving group in the nucleophilic reaction with 18F-fluoride is found to be the most efficient, rapid and clean. The reaction between the dry mixture of 18F-/K2CO3/Kryptofix prepared in the previous step and mannose triflate in anhydrous acetonitrile at ~85C provides a high yield of the 18F labeled intermediate in less than 5 minutes. An added advantage of using the acetylated mannose triflate is that after the nucleophilic displacement of the triflate group by 18F, the acetyl groups can easily be removed by hydrolysis (acid or base) to give rise to FDG. Removal of protecting groups Radiopharmaceutical Production • The final chemical step in the synthesis of FDG is the removal of the four acetyl protecting groups, which is easily accomplished through hydrolysis with either mild acid or base. Both methods are equally effective. • The alkaline hydrolysis is the most commonly used method in commercial synthesis modules since it requires less time and lower temperature. In this case, the 18F-labelled intermediate with intact acetyl groups is treated with mild base (1-2 M NaOH) at room temperature to remove the acetyl groups. The alkaline hydrolysis may be performed directly on a C-18 cartridge at room temperature instead of adding base to the reaction vessel. • One possible drawback is that alkaline hydrolysis has a potential for epimerization of FDG to [18F]Fluorodeoxymannose (FDM) which is a radiochemical impurity that should be controlled in the FDG manufacturing process. It has been shown, however, that formation of FDM is a possible only if the hydrolysis is performed at higher temperature [7]; epimerization at room temperature is negligible. FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Purification of final product Radiopharmaceutical Production • FDG Synthesizer – Cation exchange for removal of Kryptofix2.2.2 or TBA – C-18 or similar lipophilic column for removal of unhydrolyzed and partially hydrolyzed intermediates – Alumina for removal of unreacted fluoride – Ion retardation for neutralization and pH adjustment Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP FDG is purified by passing through a series of columns (e.g., SepPakTM cartridges) for removal of impurities. These columns include (not necessarily in this order): • In some synthesis modules, the unhydrolyzed intermediates are trapped on a C-18 column and impurities are washed out prior to hydrolysis. Final formulation includes adjustment of isotonicity, pH and volume adjustment. Some synthesis units utilize cation exchange and ion retardation resins to neutralize the solution, while others use buffers and addition of calculated quantity of hypertonic NaCl or Na2CO3 to achieve the required pH, isotonicity and required volume of the final product. Sterilization Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • Sterilizing filtration is performed by passing the purified FDG solution through a vented 0.22µm filter. Sterilization with steam (autoclave) may also be applied, but is not required. The filtered product is essentially the final product which is held in quarantine until the time it is qualified for patient use. QC sample removal Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP • A representative test sample is removed from the well-mixed bulk solution. If the production protocol entails dilution, sample must be drawn after dilution. Moreover, sampling must be done aseptically, ensuring not to microbiologically contaminate the final product. The sample size is usually about 0.5 mL for QC, and about 1.0 mL for retention in case of repeat tests and product complaints. Dispensing Radiopharmaceutical Production • The FDG may be dispensed either into unit doses or in multidose vials using either manual or automated systems. This process must be done in an aseptic manner. If the product is dispensed into open vials, it must be done in a class A environment. The applicable GMP regulation should be followed. Practically, the typical injection volume is 2-5 mL. • The product vial (or the syringe) and the outer lead shielding should be affixed with label containing product information, including: product name; total activity at reference time; expiration time; etc. FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Radiopharmaceutical Production QC Parameter Control During Synthesis Character FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Aim How to control during synthesis Appearance Clear, colourless, and free of particulate matter Carefully prepare the purification cartridges for efficient purification of the product. . Carefully assemble the reagents and ‘kit’ on the synthesis module during pre-synthesis set-up by practicing aseptic handling of materials to render the solution free of particulate matter and microorganisms. Radionuclidi ≥ 99% c Purity [18O]water of >95% enrichment is recommended. In case of recycling the irradiated water, the water must undergo effective purification. The use of recycled water must be validated prior to use in the production of a patient dose. . Radiopharmaceutical Production QC Parameter Control During Synthesis Character FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Aim Radiochemi ≥ 95% cal Purity Kryptofix 50µg/mL How to control during synthesis Raw materials and supplies must be controlled and care must be taken to ensure efficient purification at the end of synthesis through proper preparation and conditioning of the purification cartridges and leak-free assembly. Using only the amount of Kryptofix 2.2.2 that has been validated during set-up, and efficient purification at the end of synthesis. Radiopharmaceutical Production FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP QC Parameter Control During Synthesis Character Aim How to control during synthesis Residual solvents Acetonitrile: Controlled during synthesis (efficient 0.04%; evaporation is the key parameter, Ethanol: 0.5% which is equipment related and not necessarily controllable by the operator); The operator must ensure complete removal of solvents used for conditioning the cartridges. Impurities [18F]FDM 10%; Cl-DG 0.5 mg per maximum injectable volume [18F]FDM can be controlled by optimizing the hydrolysis temperature, time and concentration of sodium hydroxide; Cl-DG is likely to result from the presence of chloride ion in reaction mixture arising from improperly treated anion exchange resin used for collection of [18F]fluoride. Proper rinsing of the cartridge will remove the unwanted chloride ions. Radiopharmaceutical Production QC Parameter Control During Synthesis Character FDG Synthesizer Content Key Features of the Synthesis Extraction of F-18 from target water Drying of Fluoride with TBA or Cryptand Labeling of glucose with F-18 Removal of protecting groups Purification of final product Sterilization QC sample removal Dispensing QC Control During Synthesis STOP Endotoxin (pyrogen) and Sterility Aim 175 EU per maximum injectable volume How to control during synthesis Microbial contamination of the product should be controlled through use of low bioburden raw materials and supplies used in synthesis; and ensuring aseptic handling of materials and components during set-up. Return to Main Menu